Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 6
2004 9
2005 8
2006 16
2007 15
2008 20
2009 24
2010 20
2011 21
2012 18
2013 25
2014 29
2015 39
2016 36
2017 33
2018 38
2019 44
2020 46
2021 32
2022 37
2023 24
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

477 results

Results by year

Filters applied: . Clear all
Page 1
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A; GEMINI 1 Study Group. Feagan BG, et al. N Engl J Med. 2013 Aug 22;369(8):699-710. doi: 10.1056/NEJMoa1215734. N Engl J Med. 2013. PMID: 23964932 Free article. Clinical Trial.
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, Greenspan A, Allez M, Danese S, Hanauer SB, Jairath V, Kuehbacher T, Lewis JD, Loftus EV Jr, Mihaly E, Panaccione R, Scherl E, Shchukina OB, Sandborn WJ; SEAVUE Study Group. Sands BE, et al. Lancet. 2022 Jun 11;399(10342):2200-2211. doi: 10.1016/S0140-6736(22)00688-2. Lancet. 2022. PMID: 35691323 Clinical Trial.
Vedolizumab as induction and maintenance therapy for Crohn's disease.
Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A; GEMINI 2 Study Group. Sandborn WJ, et al. N Engl J Med. 2013 Aug 22;369(8):711-21. doi: 10.1056/NEJMoa1215739. N Engl J Med. 2013. PMID: 23964933 Free article. Clinical Trial.
Atopic dermatitis is associated with the clinical course of inflammatory bowel disease.
Kim KW, Koh SJ, Kang HW, Park H, Ha H, Park J, Kim K, Jun Y, Han YM, Lee HJ, Yoon H, Im JP, Park YS, Kim JW, Kim JS; Seoul National University Inflammatory Bowel Disease Research Network (SIRN) and Inflammatory Bowel Disease Research Group of Korean Association for the Study of Intestinal Disease (KASID). Kim KW, et al. Among authors: kim js. Scand J Gastroenterol. 2023 Jul-Dec;58(10):1115-1121. doi: 10.1080/00365521.2023.2209688. Epub 2023 May 11. Scand J Gastroenterol. 2023. PMID: 37165647
Ultra-bright, efficient and stable perovskite light-emitting diodes.
Kim JS, Heo JM, Park GS, Woo SJ, Cho C, Yun HJ, Kim DH, Park J, Lee SC, Park SH, Yoon E, Greenham NC, Lee TW. Kim JS, et al. Nature. 2022 Nov;611(7937):688-694. doi: 10.1038/s41586-022-05304-w. Epub 2022 Nov 9. Nature. 2022. PMID: 36352223
Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis.
Na SY, Choi CH, Song EM, Bang KB, Park SH, Kim ES, Park JJ, Keum B, Lee CK, Lee BI, Ryoo SB, Koh SJ, Choi M, Kim JS; IBD Research Group of the Korean Association for the Study of Intestinal Diseases. Na SY, et al. Among authors: kim js. Intest Res. 2023 Jan;21(1):61-87. doi: 10.5217/ir.2022.00007. Epub 2022 May 31. Intest Res. 2023. PMID: 35645321 Free PMC article. Review.
477 results